Our Surgical Experience in Desmoid Tumors

BackgroundDesmoid tumour (DT) is a locally aggressive soft tissue tumour which is histologically characterized by fibroblastic proliferation in collagen matrix. They may originate from almost any location, mainly from limbs, abdominal wall and abdominal cavity, and occur more frequently in women of childbearing age.AimsRadical resection is generally considered as the most appropriate treatment for patients with desmoid tumours. Alternative methods of treatment are available for patients with unresectable. Methods Nine patients who had DT pathology between January 2008 and January 2013 in İzmir Katip Çelebi University Atatürk Training and Research Hospital, General Surgery Clinic were included in the study.Results The mean age of the nine patients (three males and six females) was 40.1. Two patients (one male and one female) had been diagnosed with familial adenomatous polyposis (FAP), accompanied by Gardner’s syndrome (GS). Among the desmoid tumours, five (55.6 per cent) were intra-abdominally located, two (22.2 per cent) were located in the anterior abdominal wall, one (11.1 per cent) in limbs, and one (11.1 per cent) in breast.ConclusionSurgical resection in which a sufficient amount of surrounding healthy tissue is removed together with the tumour provides an effective treatment. We believe that, for those tumours which cannot be resected or incompletely resected, addition of Tamoxifen to the therapy will provide favourable results for regression

Cytopathological features of matrix-producing carcinoma of the breast

Matrix producing carcinoma (MPC) of the breast is a very rare subtype of metaplastic carcinoma with heterelogous elements, which comprises <0.1% of invasive breast carcinomas. There are very few reports describing the cytological features of MPC. In this article, we aimed to discuss cytological, histopathological and immunohistochemical features of this rare entity in a 59-year-old woman

An electronic non-interventional pharmacovigilance study of early-stage breast cancer patients on adjuvant treatment with anastrozole (Arimidex (R))

OBJECTIVE

An efficient biomarker panel for diagnosis of breast cancer using surface-enhanced laser desorption ionization time-of-flight mass spectrometry

Breast cancer (BC) is the most frequently diagnosed cancer that affects women worldwide. Early detection of BC is important to improve survival rates and decrease mortality. The aim of the present study was to investigate serum biomarkers using surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF-MS) to distinguish patients with BC from the healthy population and patients with benign breast diseases (BBDs). A total of 62 patients with invasive ductal carcinoma, as confirmed by histopathology, and 47 non-cancerous individuals (NCIs) [16 healthy controls (HCs) and 31 patients with BBD] were enrolled in the present study. Serum protein profiles were determined by SELDI-TOF-MS using an immobilized metal affinity capture array. Serum from patients with BC were compared with that from the HC group using univariate and multivariate statistical analyses. A total of 118 clusters were generated from the individual serum. Univariate analysis revealed that 5 peaks were significantly downregulated (m/z 1,452, 2,670, 3,972, 5,354 and 5,523; P<0.001) and 4 were upregulated (m/z 6,850, 7,926, 8,115 and 8,143; P<0.001) in patients with BC compared with the HC group. A comparison of patients with BC and patients with BBD revealed an additional 9 protein peaks. Among these, 3 peaks (m/z 3,972, 5,336 and 11,185) were significantly downregulated and 6 peaks (m/z 4,062, 4,071, 4,609, 6,850, 8,115 and 8,133) were significantly upregulated. A total of 3 peaks [mass-to-change ratio (m/z) 3,972, 6,850 and 8,115 (BC2)] were common in both sets. The results of the present study suggest that a 4 protein peak set [m/z 3,972, 6,850 and 8,115 (BC2) and 8,949 (BC3)] could be used to distinguish patients with BC from NCI

SELDI-TOF-MS Profiling of Metastatic Phenotype in Histopathological Subtypes of Breast Cancer

WOS: 000437989600007Background: Early detection of breast cancer is a key to the success of breast cancer management. Serum proteome analysis using Surface-Enhanced Laser Desorption/Ionization Time-Of-Flight Mass Spectrometry (SELDI-TOF-MS) generates useful information that can be utilized to describe exclusive prognostic and diagnostic biomarkers. Objective: This study aimed to use proteomics and bioinformatics to identify new biomarkers during the metastatic process of breast cancers that were classified as invasive lobular cancer or invasive ductal cancer. Method: Blood samples from 64 breast cancer patients [36 with invasive ductal cancer (14 of whom were lymph node positive); 28 with invasive lobular cancer (8 of whom were lymph node positive] were analyzed using IMAC 30 protein chips. The data acquired from the spectra were processed with univariate statistical analysis (Protein Chip Data Manager Software). Results: One-hundred-eighteen clusters were generated from the individual serum samples. Thirty-six proteins of the metastatic phenotype were found to be diagnostically accurate in cluster analysis. In the breast cancer group, a single candidate peak (m/z 1090.8) that was able to discriminate the metastatic progression was identified as a metastatic phenotype marker. Fifteen protein peaks were identified as markers to separate the histopathological subtypes as either invasive ductal cancer or invasive lobular cancer. Conclusion: In recent years, proteomic methods have rapidly become widespread in breast cancer research. This study revealed the pattern of a group of proteins that were not previously identified and are recommended as candidate markers to diagnose metastatic progression

Seldi-tof-ms profiling of metastatic phenotype in histopathological subtypes of breast cancer

WOS: 000437989600007Background: Early detection of breast cancer is a key to the success of breast cancer management. Serum proteome analysis using Surface-Enhanced Laser Desorption/Ionization Time-Of-Flight Mass Spectrometry (SELDI-TOF-MS) generates useful information that can be utilized to describe exclusive prognostic and diagnostic biomarkers. Objective: This study aimed to use proteomics and bioinformatics to identify new biomarkers during the metastatic process of breast cancers that were classified as invasive lobular cancer or invasive ductal cancer. Method: Blood samples from 64 breast cancer patients [36 with invasive ductal cancer (14 of whom were lymph node positive); 28 with invasive lobular cancer (8 of whom were lymph node positive] were analyzed using IMAC 30 protein chips. The data acquired from the spectra were processed with univariate statistical analysis (Protein Chip Data Manager Software). Results: One-hundred-eighteen clusters were generated from the individual serum samples. Thirty-six proteins of the metastatic phenotype were found to be diagnostically accurate in cluster analysis. In the breast cancer group, a single candidate peak (m/z 1090.8) that was able to discriminate the metastatic progression was identified as a metastatic phenotype marker. Fifteen protein peaks were identified as markers to separate the histopathological subtypes as either invasive ductal cancer or invasive lobular cancer. Conclusion: In recent years, proteomic methods have rapidly become widespread in breast cancer research. This study revealed the pattern of a group of proteins that were not previously identified and are recommended as candidate markers to diagnose metastatic progression

Is adjuvant chemotherapy necessary for Luminal A-like breast cancer?

Purpose: Patients with breast cancer with Luminal-A subtype have a better prognosis but poor chemotherapy response. Chemotherapy is controversial in lymph node-positive patients with Luminal-A subtype. In this retrospective study, we aimed to evaluate the efficacy and benefit of chemotherapy in the Luminal A-like subtype of breast cancer